Karyopharm Therapeutics Inc $KPTIQ
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO100%
Delay Index: of 6 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +27.7 months). See all sponsors →
Open Karyopharm Therapeutics Inc on the live radar map → 📅 $KPTIQ readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SENTRY NCT04562389 |
P3 | Active, not recruiting | Myelofibrosis | 353 | 2026-02-20 (+28 mo) |
| XPORT-EC-042 NCT05611931 |
P3 | Active, not recruiting | Endometrial Cancer | 257 | 2026-05-22 (+23 mo) |
| Selinexor NCT04562870 |
P2 | Active, not recruiting | Myelofibrosis | 112 | 2026-09 (+39 mo) |
| Selinexor (combination therapy) NCT04442022 |
P2/3 | Active, not recruiting | Relapsed/Refractory Diffuse Large B-cell Lymphoma | 501 | 2026-12 (+16 mo) |
| Selinexor NCT02227251 |
P2 | Active, not recruiting | Diffuse Large B-cell Lymphoma | 244 | 2026-12 |
| STOMP NCT02343042 |
P1/2 | Recruiting | Multiple Myeloma | 300 | 2027-04 |
| SENTRY-2 NCT05980806 |
P2 | Recruiting | Myelofibrosis; Moderate Thrombocytopenia | 58 | 2027-06 (+14 mo) |
| Selinexor NCT04414475 |
P2 | Recruiting | Multiple Myeloma, Refractory | 127 | 2028-01 (+59 mo) |